Bevacizumab and Capecitabine as First-Line Therapy in Treating Older Patients With Metastatic Colorectal Cancer

NCT00107315 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

16

Enrollment

OTHER

Sponsor class

Stopped Terminated due to low accrual

Conditions

Colorectal Cancer

Interventions

BIOLOGICAL: bevacizumab
DRUG: capecitabine

Sponsor

Roswell Park Cancer Institute